$USPH
U S PHYSICAL THERAPY INC /NV

2021 Q4 Form 10-Q Financial Statement

#000114036121037133 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $129.8M $123.6M $106.9M
YoY Change 10.5% 15.58% -8.81%
Cost Of Revenue $102.6M $96.09M $78.50M
YoY Change 16.24% 22.41% -12.68%
Gross Profit $27.19M $29.80M $30.36M
YoY Change -6.55% -1.84% 10.91%
Gross Profit Margin 20.94% 24.11% 28.39%
Selling, General & Admin $10.72M $12.87M $10.40M
YoY Change -1.67% 23.72% -1.48%
% of Gross Profit 39.41% 43.18% 34.26%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.072M $3.035M $2.740M
YoY Change 24.88% 10.77% 13.22%
% of Gross Profit 11.3% 10.18% 9.03%
Operating Expenses $10.72M $12.87M $10.40M
YoY Change -1.67% 23.72% -1.48%
Operating Profit $16.48M $16.93M $19.96M
YoY Change -9.48% -15.16% 18.68%
Interest Expense -$38.00K -$210.0K -$300.0K
YoY Change -81.0% -30.0% -153.86%
% of Operating Profit -0.23% -1.24% -1.5%
Other Income/Expense, Net $0.00 $1.216M
YoY Change
Pretax Income $18.39M $17.94M $20.04M
YoY Change -20.74% -10.5% 23.21%
Income Tax $3.946M $3.815M $4.300M
% Of Pretax Income 21.46% 21.27% 21.45%
Net Earnings $10.21M $10.01M $10.92M
YoY Change -21.44% -8.31% 20.66%
Net Earnings / Revenue 7.87% 8.1% 10.21%
Basic Earnings Per Share $0.66 $0.61
Diluted Earnings Per Share $791.1K $0.66 $0.61
COMMON SHARES
Basic Shares Outstanding 12.91M 12.91M 12.85M
Diluted Shares Outstanding 12.91M 12.85M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.57M $19.19M $30.10M
YoY Change -13.17% -36.25% 7.89%
Cash & Equivalents $28.57M $19.19M $30.10M
Short-Term Investments
Other Short-Term Assets $4.183M $3.687M $3.200M
YoY Change 10.87% 15.22% -54.92%
Inventory
Prepaid Expenses
Receivables $46.27M $56.55M $49.30M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $95.17M $79.42M $82.60M
YoY Change 8.59% -3.85% -10.74%
LONG-TERM ASSETS
Property, Plant & Equipment $22.98M $115.0M $100.3M
YoY Change 6.07% 14.64% 369.31%
Goodwill $434.7M $374.0M $336.9M
YoY Change 25.76% 11.01% 6.41%
Intangibles $86.38M $60.09M $54.06M
YoY Change 53.49% 11.15% 1.26%
Long-Term Investments $12.22M
YoY Change
Other Assets $1.578M $1.553M $1.500M
YoY Change 2.53% 3.53% 2.04%
Total Long-Term Assets $654.3M $550.7M $492.8M
YoY Change 29.12% 11.74% 5.24%
TOTAL ASSETS
Total Short-Term Assets $95.17M $79.42M $82.60M
Total Long-Term Assets $654.3M $550.7M $492.8M
Total Assets $749.4M $630.1M $575.4M
YoY Change 26.09% 9.5% 2.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.471M $1.532M $1.100M
YoY Change 397.77% 39.27% -62.07%
Accrued Expenses $45.71M $50.27M $60.24M
YoY Change -23.5% -16.55% 79.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $830.0K $672.0K $4.999M
YoY Change -83.06% -86.56% 596.24%
Total Short-Term Liabilities $83.48M $81.67M $93.20M
YoY Change -10.71% -12.37% 48.41%
LONG-TERM LIABILITIES
Long-Term Debt $117.6M $35.27M $7.509M
YoY Change 608.53% 369.64% -86.42%
Other Long-Term Liabilities $7.345M $77.65M $60.50M
YoY Change 61.82% 28.35% 8326.18%
Total Long-Term Liabilities $124.9M $35.27M $7.509M
YoY Change 491.11% 369.64% -86.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $83.48M $81.67M $93.20M
Total Long-Term Liabilities $124.9M $35.27M $7.509M
Total Liabilities $297.0M $340.3M $310.5M
YoY Change 61.06% 9.6% 65.1%
SHAREHOLDERS EQUITY
Retained Earnings $224.4M $219.3M
YoY Change 5.84%
Common Stock $151.0K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $31.63M
YoY Change 0.0%
Treasury Stock Shares $2.215M
Shareholders Equity $295.6M $289.8M $264.9M
YoY Change
Total Liabilities & Shareholders Equity $749.4M $630.1M $575.4M
YoY Change 26.09% 9.51% 1.81%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $10.21M $10.01M $10.92M
YoY Change -21.44% -8.31% 20.66%
Depreciation, Depletion And Amortization $3.072M $3.035M $2.740M
YoY Change 24.88% 10.77% 13.22%
Cash From Operating Activities $15.91M $24.95M $26.24M
YoY Change -37.38% -4.94% 47.09%
INVESTING ACTIVITIES
Capital Expenditures -$2.205M -$2.695M -$860.0K
YoY Change 2.56% 213.37% -66.27%
Acquisitions
YoY Change
Other Investing Activities -$77.67M -$8.188M -$3.970M
YoY Change 197.14% 106.25% -4.8%
Cash From Investing Activities -$79.88M -$10.88M -$4.840M
YoY Change 182.45% 124.86% -28.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 73.35M -15.29M -34.84M
YoY Change 1189.14% -56.11% 92.27%
NET CHANGE
Cash From Operating Activities 15.91M 24.95M 26.24M
Cash From Investing Activities -79.88M -10.88M -4.840M
Cash From Financing Activities 73.35M -15.29M -34.84M
Net Change In Cash 9.379M -1.231M -13.44M
YoY Change 233.77% -90.84% 91.73%
FREE CASH FLOW
Cash From Operating Activities $15.91M $24.95M $26.24M
Capital Expenditures -$2.205M -$2.695M -$860.0K
Free Cash Flow $18.11M $27.64M $27.10M
YoY Change -34.26% 1.99% 32.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
U S PHYSICAL THERAPY INC /NV
dei Entity Central Index Key
EntityCentralIndexKey
0000885978
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-11151
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0364866
dei Entity Address Address Line1
EntityAddressAddressLine1
1300 WEST SAM HOUSTON PARKWAY SOUTH
dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE 300
dei Entity Address City Or Town
EntityAddressCityOrTown
HOUSTON
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77042
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
297-7000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, $.01 par value
dei Trading Symbol
TradingSymbol
USPH
dei Security Exchange Name
SecurityExchangeName
NYSE
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12911608
usph Proceeds From Short Swing Profit Settlement
ProceedsFromShortSwingProfitSettlement
20000
usph Proceeds From Short Swing Profit Settlement
ProceedsFromShortSwingProfitSettlement
0
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usph Number Of Third Party Facilities
NumberOfThirdPartyFacilities
35
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
219338000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
212015000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
usph Percentage Of General Partnership Interest Owned
PercentageOfGeneralPartnershipInterestOwned
0.01
usph Resolution Of Payor Matter
ResolutionOfPayorMatter
1216000
usph Resolution Of Payor Matter
ResolutionOfPayorMatter
0
us-gaap Restructuring Charges
RestructuringCharges
2066000
CY2021Q3 us-gaap Restructuring Charges
RestructuringCharges
5000
CY2020Q3 us-gaap Restructuring Charges
RestructuringCharges
79000
us-gaap Restructuring Charges
RestructuringCharges
20000
CY2021Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1859000
CY2021Q3 usph Relief Funds
ReliefFunds
0
CY2020Q3 usph Relief Funds
ReliefFunds
390000
usph Relief Funds
ReliefFunds
0
usph Relief Funds
ReliefFunds
8349000
CY2021Q3 us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
0
CY2020Q3 us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
18000
us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
0
us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
1091000
CY2021Q3 usph Resolution Of Payor Matter
ResolutionOfPayorMatter
1216000
CY2020Q3 usph Resolution Of Payor Matter
ResolutionOfPayorMatter
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6280000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2019 usph Number Of Regions
NumberOfRegions
6
CY2020 usph Number Of Regions
NumberOfRegions
6
CY2020 usph Number Of Regions
NumberOfRegions
6
CY2021Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations
InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations
0
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
17938000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
20042000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
54807000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
42317000
us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
670000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
284811000
us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
914000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-113000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-346000
usph Gain On Sale Of Partnership Interest Net Of Tax
GainOnSaleOfPartnershipInterestNetOfTax
0
usph Gain On Sale Of Partnership Interest Net Of Tax
GainOnSaleOfPartnershipInterestNetOfTax
1091000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1859000
us-gaap Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates
ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
69000
us-gaap Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates
ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
54000
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
136000
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
1118000
CY2021Q3 usph Notes Payable Related To Purchase Of Redeemable Non Controlling Interest
NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterest
1302000
CY2020Q3 usph Notes Payable Related To Purchase Of Redeemable Non Controlling Interest
NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterest
137000
CY2021Q3 usph Notes Payable Related To Purchase Of Non Controlling Interest Permanent Equity
NotesPayableRelatedToPurchaseOfNonControllingInterestPermanentEquity
0
CY2020Q3 usph Notes Payable Related To Purchase Of Non Controlling Interest Permanent Equity
NotesPayableRelatedToPurchaseOfNonControllingInterestPermanentEquity
699000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
386000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2021Q3 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-1542000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2877000
CY2021Q3 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
668000
CY2021Q3 usph Sale Of Non Controlling Interest Net Of Purchases
SaleOfNonControllingInterestNetOfPurchases
261000
CY2021Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
4906000
CY2021Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1730000
CY2021Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
-4000
CY2021Q3 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1509000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
10009000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
290617000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
277630000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-8852000
us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
668000
usph Sale Of Non Controlling Interest Net Of Purchases
SaleOfNonControllingInterestNetOfPurchases
261000
CY2021Q3 usph Number Of Closed Clinics Sold
NumberOfClosedClinicsSold
2
usph Aggregate Sale Price Of Cinics
AggregateSalePriceOfCinics
100000
CY2021Q3 usph Number Of Clinics Operated
NumberOfClinicsOperated
579
CY2021Q3 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
39
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
13934000
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
4912000
usph Short Swing Profit Settlement
ShortSwingProfitSettlement
20000
us-gaap Stockholders Equity Other
StockholdersEquityOther
-20000
usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
4194000
us-gaap Net Income Loss
NetIncomeLoss
30618000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
290617000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
256688000
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2020Q3 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-3207000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1936000
CY2020Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
2309000
CY2020Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
20000
CY2020Q3 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1828000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
10916000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
265872000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
241701000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
867000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5325000
usph Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans
TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans
486000
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
4110000
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
4352000
us-gaap Stockholders Equity Other
StockholdersEquityOther
-99000
usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
3889000
us-gaap Net Income Loss
NetIncomeLoss
22164000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
265872000
CY2021Q2 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
8
CY2021Q3 usph Deferment Depositing Of Employer Share Social Security Taxes
DefermentDepositingOfEmployerShareSocialSecurityTaxes
4100000
CY2021Q3 usph Deferment Depositing Of Employer Share Social Security Taxes1
DefermentDepositingOfEmployerShareSocialSecurityTaxes1
4200000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1900000
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021Q3 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q2 usph Percentage Of Payment Reduction Waived Through Enacted Legislation
PercentageOfPaymentReductionWaivedThroughEnactedLegislation
0.02
CY2021Q3 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-2071000
CY2020Q3 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-4297000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
125893000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
108929000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
365189000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
305503000
usph Estimated Percentage Of Decrease In Payment
EstimatedPercentageOfDecreaseInPayment
0.035
usph Period Of Federal Debt Ceiling In Connection With Deficit Reductions
PeriodOfFederalDebtCeilingInConnectionWithDeficitReductions
P10Y
usph Amount Of Reductions In Federal Spending
AmountOfReductionsInFederalSpending
1200000000000
usph Reduction In Medicare Spending Percentage
ReductionInMedicareSpendingPercentage
0.02
CY2013Q2 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2015Q4 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2018Q1 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q3 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q2 usph Percentage Of Payment Reduction Waived Through Enacted Legislation
PercentageOfPaymentReductionWaivedThroughEnactedLegislation
0.02
usph Percentage Of Increase In Payment Adjustment For Therapists Participating In Merit Based Incentive Payment System
PercentageOfIncreaseInPaymentAdjustmentForTherapistsParticipatingInMeritBasedIncentivePaymentSystem
0.01
usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
usph Reduction In Combined Physical Therapy Speech Language Pathology Expenses
ReductionInCombinedPhysicalTherapySpeechLanguagePathologyExpenses
3000
usph Percentage Of Practice Expense Component Of Relative Value Unit
PercentageOfPracticeExpenseComponentOfRelativeValueUnit
1
usph Percentage Reduction For Service In Office Or Other Non Institutional Settings
PercentageReductionForServiceInOfficeOrOtherNonInstitutionalSettings
0.50
usph Percentage Of Payment For Outpatient Therapy Services
PercentageOfPaymentForOutpatientTherapyServices
0.85
CY2021Q3 usph Net Revenue From Medicare
NetRevenueFromMedicare
36200000
CY2020Q3 usph Net Revenue From Medicare
NetRevenueFromMedicare
27500000
usph Net Revenue From Medicare
NetRevenueFromMedicare
98300000
usph Net Revenue From Medicare
NetRevenueFromMedicare
71900000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
10009000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
10916000
us-gaap Net Income Loss
NetIncomeLoss
30618000
us-gaap Net Income Loss
NetIncomeLoss
22164000
usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-11889000
usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
1175000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1859000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12829000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12829000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2555
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.2625
CY2021Q3 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-529000
CY2020Q3 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-1228000
usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-3038000
usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
308000
CY2021Q3 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
8467000
CY2020Q3 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
7847000
usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
21767000
usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
23031000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.66
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.66
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.80
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12909000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12909000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12847000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12847000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12894000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12894000
CY2020Q4 us-gaap Goodwill
Goodwill
345646000
CY2019Q4 us-gaap Goodwill
Goodwill
317676000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
29363000
CY2020 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
28540000
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-962000
CY2020 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
1289000
CY2021Q3 us-gaap Goodwill
Goodwill
374047000
CY2020Q4 us-gaap Goodwill
Goodwill
345646000
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1900000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
60086000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
56280000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
995000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
834000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2732000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2547000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
31478000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
24646000
CY2021Q3 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
6390000
CY2020Q4 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
5756000
CY2021Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1839000
CY2020Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
2113000
CY2021Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
686000
CY2020Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1333000
CY2021Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
3977000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
5715000
CY2021Q3 usph Medicare Accelerated And Advance Payments Program Funds Payable
MedicareAcceleratedAndAdvancePaymentsProgramFundsPayable
0
CY2020Q4 usph Medicare Accelerated And Advance Payments Program Funds Payable
MedicareAcceleratedAndAdvancePaymentsProgramFundsPayable
14054000
CY2021Q3 usph Deferred Employer Payroll Taxes Caresact
DeferredEmployerPayrollTaxesCARESACT
4170000
CY2020Q4 usph Deferred Employer Payroll Taxes Caresact
DeferredEmployerPayrollTaxesCARESACT
4170000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1727000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1959000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
50267000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
59746000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
35937000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
21495000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
672000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
4899000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
35265000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16596000
CY2021Q3 us-gaap Line Of Credit Facility Unused Capacity Commitment Fee Percentage
LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
0.003
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
672000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2265000
CY2021Q3 usph Long Term Debt Maturities Repayments Of Principal In Year Six
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix
33000000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
35937000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
8114000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
7470000
us-gaap Operating Lease Cost
OperatingLeaseCost
23738000
us-gaap Operating Lease Cost
OperatingLeaseCost
23097000
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
440000
CY2020Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
389000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1169000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
898000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1670000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1436000
us-gaap Variable Lease Cost
VariableLeaseCost
4908000
us-gaap Variable Lease Cost
VariableLeaseCost
4482000
CY2021Q3 us-gaap Lease Cost
LeaseCost
10224000
CY2020Q3 us-gaap Lease Cost
LeaseCost
9295000
us-gaap Lease Cost
LeaseCost
29815000
us-gaap Lease Cost
LeaseCost
28477000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
8257000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
30684000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
8354000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
7696000
us-gaap Operating Lease Payments
OperatingLeasePayments
24724000
us-gaap Operating Lease Payments
OperatingLeasePayments
22041000
CY2021Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13269000
CY2020Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3162000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
34112000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
22238000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
25084000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
18462000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
12145000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
11868000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
106500000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6094000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
100406000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.029
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.032
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.029
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.032
CY2021Q3 us-gaap Revenues
Revenues
123580000
CY2020Q3 us-gaap Revenues
Revenues
106925000
us-gaap Revenues
Revenues
357578000
us-gaap Revenues
Revenues
299759000
CY2021Q3 us-gaap Gross Profit
GrossProfit
29799000
CY2020Q3 us-gaap Gross Profit
GrossProfit
30357000
us-gaap Gross Profit
GrossProfit
89999000
us-gaap Gross Profit
GrossProfit
65332000
CY2021Q3 us-gaap Assets
Assets
630098000
CY2020Q3 us-gaap Assets
Assets
575438000
CY2021Q3 us-gaap Assets
Assets
630098000
CY2020Q3 us-gaap Assets
Assets
575438000
CY2021Q1 usph Short Swing Profit Settlement
ShortSwingProfitSettlement
20000
CY2008Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
2250000
CY2009Q1 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1200000
CY2009Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
859499
usph Additional Estimated Repurchase Of Common Stock
AdditionalEstimatedRepurchaseOfCommonStock
135624
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
110.60
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0

Files In Submission

Name View Source Status
0001140361-21-037133-index-headers.html Edgar Link pending
0001140361-21-037133-index.html Edgar Link pending
0001140361-21-037133.txt Edgar Link pending
0001140361-21-037133-xbrl.zip Edgar Link pending
brhc10030340_10q.htm Edgar Link pending
brhc10030340_10q_htm.xml Edgar Link completed
brhc10030340_ex31-1.htm Edgar Link pending
brhc10030340_ex31-2.htm Edgar Link pending
brhc10030340_ex31-3.htm Edgar Link pending
brhc10030340_ex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usph-20210930.xsd Edgar Link pending
usph-20210930_cal.xml Edgar Link unprocessable
usph-20210930_def.xml Edgar Link unprocessable
usph-20210930_lab.xml Edgar Link unprocessable
usph-20210930_pre.xml Edgar Link unprocessable